揭开高钙血症性脑病的奥秘:来自三级保健中心的临床经验。

{"title":"揭开高钙血症性脑病的奥秘:来自三级保健中心的临床经验。","authors":"","doi":"10.33140/an.06.02.10","DOIUrl":null,"url":null,"abstract":"Background Hypercalcemic encephalopathy is a rare but clinically significant condition characterized by a range of complex symptoms due to elevated serum calcium levels. The causes of this condition can stem from various underlying factors, with the most common being primary hyperparathyroidism, malignancies, and granulomatous diseases. This study aims to provide a comprehensive clinical profile of hypercalcemic encephalopathy by examining a cohort of patients presenting at a tertiary care center. Results We analyzed etiologies, clinical manifestations, and short-term outcomes in 32 patients with a mean age of 32.45 years. The study revealed that malignancy-related hypercalcemia was the predominant cause in a significant portion of the cases (46.8%), indicating that cancer-associated mechanisms play a substantial role in the development of hypercalcemic encephalopathy. Hyperparathyroidism, accounted for 34.3% of the cases, followed by granulomatous disease, which was the underlying factor in 12.5% of the cases. Unfortunately, six patients experienced mortality during the study. The primary reasons for these unfortunate outcomes were related to hypercalcemia itself, highlighting critical importance of its proper management. Conclusion The treatment responses observed in the study provided valuable insights. About 37.5% of the patients responded positively to the administration of intravenous fluids and calcitonin, a hormone involved in calcium regulation. However, for those who did not respond to these standard treatments, the introduction of denosumab, a medication that inhibits bone resorption and can lower calcium levels, yielded positive outcomes. This suggests the potential utility of denosumab in cases where traditional treatments are ineffective. Overall, this study significantly contributes to our understanding of hypercalcemic encephalopathy by delving into its clinical features, the range of underlying causes, responses to treatment, and patient outcomes. The findings underscore the importance of recognizing this condition promptly and implementing tailored interventions to ensure optimal management and improved patient care","PeriodicalId":93246,"journal":{"name":"Advances in neurology and neuroscience","volume":"312 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Unraveling the Mysteries of Hypercalcemic Encephalopathy: A Clinical Experience from A Tertiary Care Center.\",\"authors\":\"\",\"doi\":\"10.33140/an.06.02.10\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background Hypercalcemic encephalopathy is a rare but clinically significant condition characterized by a range of complex symptoms due to elevated serum calcium levels. The causes of this condition can stem from various underlying factors, with the most common being primary hyperparathyroidism, malignancies, and granulomatous diseases. This study aims to provide a comprehensive clinical profile of hypercalcemic encephalopathy by examining a cohort of patients presenting at a tertiary care center. Results We analyzed etiologies, clinical manifestations, and short-term outcomes in 32 patients with a mean age of 32.45 years. The study revealed that malignancy-related hypercalcemia was the predominant cause in a significant portion of the cases (46.8%), indicating that cancer-associated mechanisms play a substantial role in the development of hypercalcemic encephalopathy. Hyperparathyroidism, accounted for 34.3% of the cases, followed by granulomatous disease, which was the underlying factor in 12.5% of the cases. Unfortunately, six patients experienced mortality during the study. The primary reasons for these unfortunate outcomes were related to hypercalcemia itself, highlighting critical importance of its proper management. Conclusion The treatment responses observed in the study provided valuable insights. About 37.5% of the patients responded positively to the administration of intravenous fluids and calcitonin, a hormone involved in calcium regulation. However, for those who did not respond to these standard treatments, the introduction of denosumab, a medication that inhibits bone resorption and can lower calcium levels, yielded positive outcomes. This suggests the potential utility of denosumab in cases where traditional treatments are ineffective. Overall, this study significantly contributes to our understanding of hypercalcemic encephalopathy by delving into its clinical features, the range of underlying causes, responses to treatment, and patient outcomes. The findings underscore the importance of recognizing this condition promptly and implementing tailored interventions to ensure optimal management and improved patient care\",\"PeriodicalId\":93246,\"journal\":{\"name\":\"Advances in neurology and neuroscience\",\"volume\":\"312 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in neurology and neuroscience\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33140/an.06.02.10\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in neurology and neuroscience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33140/an.06.02.10","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景:高钙血症性脑病是一种罕见但临床意义重大的疾病,其特征是由血清钙水平升高引起的一系列复杂症状。这种情况的原因可能源于各种潜在因素,最常见的是原发性甲状旁腺功能亢进、恶性肿瘤和肉芽肿性疾病。本研究的目的是提供一个全面的临床资料,高钙血症脑病通过检查的队列患者呈现在三级保健中心。结果我们分析了32例患者的病因、临床表现和短期预后,平均年龄32.45岁。研究显示,在相当一部分病例(46.8%)中,恶性肿瘤相关的高钙血症是主要原因,表明癌症相关机制在高钙血症脑病的发展中起重要作用。甲状旁腺功能亢进占34.3%,其次是肉芽肿性疾病,占12.5%。不幸的是,6名患者在研究期间死亡。这些不幸结果的主要原因与高钙血症本身有关,强调了其适当管理的重要性。结论本研究观察到的治疗效果提供了有价值的见解。约37.5%的患者对静脉输液和降钙素(一种参与钙调节的激素)有积极反应。然而,对于那些对这些标准治疗没有反应的患者,引入denosumab(一种抑制骨吸收并能降低钙水平的药物)产生了积极的结果。这表明在传统治疗无效的情况下,denosumab具有潜在的效用。总的来说,本研究通过深入研究高钙血症脑病的临床特征、潜在原因、治疗反应和患者预后,显著地促进了我们对高钙血症脑病的理解。研究结果强调了及时认识到这种情况并实施量身定制的干预措施以确保最佳管理和改善患者护理的重要性
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Unraveling the Mysteries of Hypercalcemic Encephalopathy: A Clinical Experience from A Tertiary Care Center.
Background Hypercalcemic encephalopathy is a rare but clinically significant condition characterized by a range of complex symptoms due to elevated serum calcium levels. The causes of this condition can stem from various underlying factors, with the most common being primary hyperparathyroidism, malignancies, and granulomatous diseases. This study aims to provide a comprehensive clinical profile of hypercalcemic encephalopathy by examining a cohort of patients presenting at a tertiary care center. Results We analyzed etiologies, clinical manifestations, and short-term outcomes in 32 patients with a mean age of 32.45 years. The study revealed that malignancy-related hypercalcemia was the predominant cause in a significant portion of the cases (46.8%), indicating that cancer-associated mechanisms play a substantial role in the development of hypercalcemic encephalopathy. Hyperparathyroidism, accounted for 34.3% of the cases, followed by granulomatous disease, which was the underlying factor in 12.5% of the cases. Unfortunately, six patients experienced mortality during the study. The primary reasons for these unfortunate outcomes were related to hypercalcemia itself, highlighting critical importance of its proper management. Conclusion The treatment responses observed in the study provided valuable insights. About 37.5% of the patients responded positively to the administration of intravenous fluids and calcitonin, a hormone involved in calcium regulation. However, for those who did not respond to these standard treatments, the introduction of denosumab, a medication that inhibits bone resorption and can lower calcium levels, yielded positive outcomes. This suggests the potential utility of denosumab in cases where traditional treatments are ineffective. Overall, this study significantly contributes to our understanding of hypercalcemic encephalopathy by delving into its clinical features, the range of underlying causes, responses to treatment, and patient outcomes. The findings underscore the importance of recognizing this condition promptly and implementing tailored interventions to ensure optimal management and improved patient care
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信